DIXi Group Parnters with Aleva Neurotherapeutics

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

DIXI Holding Le Locle SA and Aleva Neurotherapeutics SA have co-founded Adept Neuro SA, a Joint Venture dedicated to developing  a new generation of Stereo-Electro-Encephalo-Graphie (SEEG) electrodes which will facilitate localization and thermocoagulation of epileptogenic zones.

Aleva Neurotherapeutics, a spin-off of the Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory, has developed a unique technology for the manufacture of electrodes allowing precise stimulation of the deep brain. Aleva’s electrodes are based on MEMS technology, which allows great flexibility of design and miniaturization, opening the door to new product development avenues and cost efficient industrialization of the manufacturing process.

DIXI Medical SAS in Besançon is the world leader in the manufacture of intracerebral electrodes for SEEG. The current conventional mode of production limits the company’s ability to meet the demand of a rapidly growing market and prohibits the necessary evolution in therapeutic modalities that only the nanotech dimension can facilitate.

Adept Neuro has exclusive intellectual property rights developed by Aleva Neurotherapeutics in the field of epilepsy. DIXI Holding will ensure the full financing of the joint venture and will gradually become the sole shareholder, while DIXI Medical SAS will ensure the exclusive production and distribution of products developed by Adept Neuro.

Dr André Mercanzini, CEO of Aleva Neurotherapeutics SA (Lausanne, Switzerland) explains the importance of the partnership: “Our technology has demonstrated its clinical efficacy in the most demanding applications of neurosurgery. With the long and pioneering experience of Dixi in Epilepsy, we are sure to transform the lives of patients for the better”

Mr Frédéric Koehn COO of DIXI Holding SA (Le Locle, Switzerland) stressed that this investment is a major sign of the Dixi Group’s new ambitions: “Dixi is dedicated to improving the lives of epileptic patients by providing new technologies to Neurologists and Neurosurgeons. We aim to become a major integrated player for the diagnostic and surgical treatment of Epilepsy.”

Adept Neuro SA will be based at the EPFL Innovation Park in Lausanne, Switzerland.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.